The approach of blocking CD47 with SIRPa-Fc or anti-CD47 antibodies is showing promise as a cancer treatment by inhibiting the 'do not eat' signal and promoting phagocytosis. However, this method is associated with hematological toxicities, particularly anemia and thrombocytopenia. Lemzoparlimab, also known as TJ011133 or TJC4, is a fully human IgG4 antibody targeting CD47 with a unique binding epitope and the advantage of sparing red blood cells, potentially distinguishing it from other CD47-targeting therapies.
Specifications
Catalog Number:
KB-1032
Antibodies Name:
lemzoparlimab
Host Cell Line:
EXPI-CHO
Target:
CD47
Species Reactivity:
Human
Application:
ELISA | FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | FACS
Characterization
Application
References
1.A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results.
2.A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results.
